LEADER 04939nam 2201321z- 450 001 9910580212603321 005 20231214133459.0 035 $a(CKB)5690000000011962 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/87516 035 $a(EXLCZ)995690000000011962 100 $a20202207d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aOncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (346 p.) 311 $a3-0365-4532-8 311 $a3-0365-4531-X 330 $aThe road of acceptance of oncologic thermotherapy/hyperthermia as a synergistic modality in combination with standard oncologic therapies is still bumpy. This is partially due to the lack of level I evidence from international, multicentric, randomized clinical trials including large patient numbers and a long term follow-up. Therefore we need more level I EVIDENCE from clinical trials, we need HARMONISATION and global acceptance for existing technologies and a common language understood by all stakeholders and we need INNOVATION in the fields of biology, clinics and technology to move thermotherapy/hyperthermia forward. This is the main focus of this reprint. In this reprintyou find carefully selected and peer-reviewed contributions from Africa, America, Asia, and Europe. The published papers from leading scientists from all over the world covering a broad range of timely research topics might also help to strengthen thermotherapy on a global level. 517 $aOncologic Thermoradiotherapy 606 $aMedicine$2bicssc 606 $aOncology$2bicssc 610 $aperfusion estimation 610 $atemperature monitoring 610 $aconductivity reconstruction 610 $asystems medicine 610 $aimmune system in silico 610 $aperceptron 610 $aantigen pattern 610 $adanger signal 610 $afractionation 610 $aimmune response 610 $ahead and neck cancer 610 $ahyperthermia 610 $areirradiation 610 $atreatment outcome 610 $ahyperthermia treatment planning 610 $aadaptive planning 610 $atemperature optimization 610 $alow-middle-income group countries 610 $acancer 610 $aradiotherapy 610 $achemotherapy 610 $arecurrent breast cancers 610 $acervical cancer 610 $ahead and neck cancers 610 $acost-effective 610 $ameta-analysis 610 $aintensity-modulated radiotherapy 610 $aprostate cancer 610 $athermal dose 610 $athermometric parameters 610 $apreclinical data 610 $aclinical evidence 610 $amodulated electro-hyperthermia 610 $aabscopal effect 610 $alocally advanced cervical cancer 610 $aresource-constrained setting 610 $aradiosensitiser 610 $arectal cancer 610 $achemoradiotherapy 610 $atumour control 610 $aloco-regional hyperthermia 610 $aoncology 610 $acellular selection 610 $abioelectromagnetics 610 $acomplexity 610 $aimmune-effects 610 $amoderate hyperthermia 610 $adeep hyperthermia 610 $aradiative hyperthermia 610 $apatterns of care 610 $areimbursement 610 $aregional hyperthermia 610 $aneoadjuvant chemoradiation 610 $asurvival 610 $ainduced 610 $abrachytherapy 610 $aprostatic neoplasms 610 $ainterstitial hyperthermia 610 $atreatment plan optimization 610 $aprostate 610 $athermoradiotherapy 610 $alinear quadratic model 610 $abiological modeling 610 $athermal dosimetry 610 $ahypoxia 610 $aradiation therapy 610 $areoxygenation 610 $aperfusion 610 $aoxygen consumption rate 610 $alocal tumor control 610 $abiomarker 610 $aimmune phenotype 610 $ahyperthermia treatment sequence 610 $abreast cancer 610 $aimmune checkpoint molecules 610 $adendritic cell activation 615 7$aMedicine 615 7$aOncology 700 $aBodis$b Stephan$4edt$01326273 702 $aGhadjar$b Pirus$4edt 702 $aVan Rhoon$b Gerard C$4edt 702 $aBodis$b Stephan$4oth 702 $aGhadjar$b Pirus$4oth 702 $aVan Rhoon$b Gerard C$4oth 906 $aBOOK 912 $a9910580212603321 996 $aOncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation$93037243 997 $aUNINA